CompletedNCT06391593
ALTO-203 safety study for adults with major depression
About this title
Read the official source — NCT06391593Medication studyAges 25–64United States
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 25 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Tucson and 14 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: March 25, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 69
- Sponsor
- Alto Neuroscience
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 25 Years to 64 Years
- Official registry ID
- NCT06391593
- Official title
Show the full official title
Double-Blind, Single and Multiple Dose Study to Determine Pharmacodynamic Markers, Pharmacokinetic Parameters, and Safety of ALTO-203 in Patients With Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Tucson · Oceanside · Torrance
12 more locations
- Clermont
- Orlando
- Atlanta
- Pikesville
- Las Vegas
- Marlton
- Princeton
- Westlake
- Austin
- Houston
- Clinton
- Bellevue
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Alto Neuroscience.
Did this study involve medication?
Yes. The study involved medication, including ALTO-203 25 μg, ALTO-203 75 μg and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 25 years to 64 years. Other eligibility criteria applied.
